FEMISOL
LETROZOLE
Public price
630,00 MAD
Active substance
LETROZOLE
Laboratory
ZENITH PHARMA
Reimbursable
What is this medicine?
A nonsteroidal competitive inhibitor of the aromatase enzyme system that inhibits the conversion of androgens to estrogens.
Verified summary
LETROZOLE, COMPRIME PELLICULE, 2,5 MG, Boite de 30
Common uses
Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer, extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy, and first and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.
Class
aromatase inhibitor
Laboratory
ZENITH PHARMA
Availability note
Reimbursable
Hospital price
418,00 MAD
Strength
2,5 MG
Form
COMPRIME PELLICULE
Presentation
Boite de 30
Commercial status
Non Commercialisé
This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.
Price history
Reference price recorded since 2026-06-01: 630,00 MAD
Medicines with the same active substance
LETROZOLE GT
2,5 MG · BOITE DE 60
1,11 MAD
LETROZOLE GT
2,5 MG · BOITE DE 10
211,00 MAD
LETROZOLE PHARMED
2,5 MG · BOITE DE 30
614,00 MAD
LETROZOLE ZENITH
2,5 MG · BOITE DE 30
630,00 MAD
LETROZOLE ZENITH 2.5 MG
2.5 MG · Boîte de 30
630,00 MAD
LEZORA
2,5 MG · BOITE DE 28
632,00 MAD
ELOZOLE
2,5 MG · BOITE DE 30
712,00 MAD
LEFTARA
2,5 MG · BOITE DE 30
712,00 MAD
LEFTARA 2.5 MG
2.5 MG · Boite de 30
712,00 MAD
FEMOLET
2,5 MG · BOITE DE 30
713,00 MAD
LETROZOLE COOPER
2,5 MG · BOITE DE 30
713,00 MAD
LETROZOLE GT
2.5 MG · 1 BOITE 30 COMPRIME SECABLE
713,00 MAD